Japan Diabetes Drugs and Devices Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 4.80 Billion |
| Market Size (2029) | USD 6.40 Billion |
| CAGR (2024 - 2029) | > 3.20 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Japan Diabetes Drugs and Devices Market Analysis
The Japan Diabetes Drugs And Devices Market size is estimated at USD 4.80 billion in 2024, and is expected to reach USD 6.40 billion by 2029, growing at a CAGR of greater than 3.20% during the forecast period (2024-2029).
Japan is experiencing a significant rise in its diabetes population, with the country facing a growing epidemic of both type 1 and type 2 diabetes.
Several factors contribute to the increasing prevalence of diabetes in Japan. Rapid urbanization, sedentary lifestyles, unhealthy dietary habits, and genetic predispositions are among the key drivers of the diabetes epidemic. Additionally, factors such as obesity, high rates of gestational diabetes, and limited access to healthcare and preventive services in certain regions exacerbate the problem.
Type 2 diabetes accounts for the majority of diabetes cases in Japan, with estimates suggesting that over 90% of individuals with diabetes have type 2 diabetes. This form of diabetes is closely linked to lifestyle factors such as obesity, physical inactivity, and poor dietary habits, which are becoming increasingly prevalent in Japan urban and rural populations.
The rising diabetes population in Japan poses significant challenges for the country's healthcare system and economy. Diabetes is associated with a higher risk of cardiovascular disease, stroke, kidney disease, and other complications, placing a substantial burden on healthcare resources and increasing healthcare costs. Addressing the diabetes epidemic requires comprehensive public health strategies focused on prevention, early detection, lifestyle modification, and access to quality healthcare services for all segments of the population.
Thus, the above factors are expected to drive market growth over the forecast period.
Japan Diabetes Drugs and Devices Market Trends
The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period
Continuous glucose monitoring sensors use glucose oxidase to measure blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with platinum in the sensor to produce an electrical signal sent to a transmitter. The sensor is the most important part of any continuous blood glucose monitoring device. Researchers seek to find and develop alternatives to electrochemical glucose sensors to make CGM sensors more affordable, minimally invasive, and user-friendly. Optical measurement is a promising platform for glucose measurement.
Several techniques with high potential for continuous glucose measurement have been reported, including spectroscopy, fluorescence, and holographic techniques. Eversense, a fluorescence based CGM sensor developed by Sensonics Company, has a much longer lifetime than electrochemical sensors. Technological advances in improving sensor accuracy are expected to drive the growth of the segment during the forecast period.
With CGM, a small sensor is inserted into the abdomen or arm using a small plastic cannula that penetrates the top layer of the skin. An adhesive patch holds the sensor in place, allowing it to measure glucose levels in interstitial fluid day and night. In general, the sensor should be replaced every 7-14 days. A small, reusable transmitter attached to the sensor allows the system to wirelessly transmit real-time readings to a monitor displaying blood glucose data. Some systems have their own monitor, while others show information via smartphone apps.
The frequency of monitoring blood glucose levels depends on the type of diabetes and is different for each patient. Patients with type 1 diabetes should monitor their blood sugar levels with regular checks and adjust their insulin dosage accordingly.
His CGM device now details blood glucose patterns and trends compared to routine blood glucose monitoring at set intervals. In addition, current continuous blood glucose monitors can retroactively check blood glucose trends by downloading data or providing real-time images of blood glucose levels via the receiver display. New technologies like cell phone integration make continuous glucose monitoring devices increasingly affordable. This is likely to drive the growth of the segment during the forecast period.
Rising diabetes prevalence
Diabetes is classified as an important health problem by the Ministry of Health, Labor and Welfare. The high prevalence of type 2 diabetes comes with a significant economic burden. The cost of diabetes increases in patients with comorbidities such as hypertension and hyperlipidemia and those who develop complications.
As the number of complications increases, so does the price. In Japan, a well-developed health insurance system covers all medical expenses for diabetes, and people with diabetes can see a doctor for free. Insulin self-injection therapy has also been legalized and covered by health insurance companies. These advantages have led to introducing of these products into the Japanese market.
Oral antidiabetic agents are available worldwide and are recommended for use when lifestyle management and escalation of type 2 diabetes treatment are required. Oral formulations are usually the drugs of first choice for the treatment of type 2 diabetes because of their wide range of efficacy, safety, and mechanisms of action. Antidiabetic drugs help people with diabetes control their condition and reduce the risk of diabetic complications. People with diabetes may need to take antidiabetic drugs throughout their lives to control blood sugar levels and avoid hypoglycemia or hyperglycemia. Oral hypoglycemic agents have the advantage of being easy to use and inexpensive. This has made them an attractive alternative to insulin, leading to greater acceptance and improved adherence.
In Japan, the prevalence of diabetes is increasing in all age groups due to a growing obese population, unhealthy diets, and sedentary lifestyles. Diabetes is a significant concern due to its high prevalence and increasing financial burden on clinical systems, individuals, and governments. The Japanese healthcare system includes several disease control programs run by the Japan Diabetes Education and Care Association. Japan is one of the leaders in the Asia-Pacific region when it comes to public health policy for people with diabetes. The country is raising public awareness and implementing preventive measures focused on lifestyle and dietary changes that can reduce the likelihood of adult-onset diabetes.
The increasing diabetes prevalence and the above factors will likely drive segment growth over the forecast period.
Japan Diabetes Drugs and Devices Industry Overview
Large companies such as Abbott and Medtronic have made numerous mergers, acquisitions, and partnerships to gain market dominance while adhering to organic growth strategies. The manufacturers of insulin delivery devices are spending a huge amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may also assist to enable insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness equipment well suited to the FreeStyle Libre portfolio of products.
Japan Diabetes Drugs and Devices Market Leaders
Medtronics
Roche
NovoNordisk
Sanofi
Omnipod
*Disclaimer: Major Players sorted in no particular order
Japan Diabetes Drugs and Devices Market News
- March 2023: Health2Sync developed the latest version of the Health2Sync App that integrates insulin data from Mallya Cap (insulin cartridge) developed by Biocorp and commercialized in Japan by Novo Nordisk.
- September 2022: Japan's health ministry approved Eli Lilly's diabetes drug Mounjaro (tirzepatide). Mitsubishi Tanabe Pharma Corporation distributes and sells Mounjaro in Japan according to its sales collaboration agreement with Eli Lilly Japan, signed in July 2022. The drug is administered in Japan using ATEOS, a single-use autoinjector device.
Japan Diabetes Drugs And Devices Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.3 Porter's Five Forces Analysis
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Consumers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitute Products and Services
4.3.5 Intensity of Competitive Rivalry
5. Market Segmentation (Market Size by Value - USD)
5.1 Devices
5.1.1 Monitoring Devices
5.1.1.1 Self-monitoring Blood Glucose Devices
5.1.1.2 Continuous Blood Glucose Monitoring
5.1.2 Management Devices
5.1.2.1 Insulin Pump
5.1.2.2 Insulin Syringes
5.1.2.3 Insulin Cartridges
5.1.2.4 Disposable Pens
5.2 Drugs
5.2.1 Oral Anti-Diabetes Drugs
5.2.2 Insulin Drugs
5.2.3 Combination Drugs
5.2.4 Non-Insulin Injectable Drugs
6. Market Indicators
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Novo Nordisk
7.1.2 Medtronic
7.1.3 Insulet
7.1.4 Tandem
7.1.5 Ypsomed
7.1.6 Novartis
7.1.7 Sanofi
7.1.8 Eli Lilly
7.1.9 Abbottt
7.1.10 Roche
7.1.11 Astrazeneca
7.1.12 Dexcom
- *List Not Exhaustive
7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Japan Diabetes Drugs and Devices Industry Segmentation
Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be given several times a day, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections such as insulin. Japan diabetes drugs and devices market by drugs, and devices. The report offers the value (in USD) and Volume (in unit) for the above segments.
| Devices | ||||||
| ||||||
|
| Drugs | |
| Oral Anti-Diabetes Drugs | |
| Insulin Drugs | |
| Combination Drugs | |
| Non-Insulin Injectable Drugs |
Japan Diabetes Drugs And Devices Market Research Faqs
How big is the Japan Diabetes Drugs And Devices Market?
The Japan Diabetes Drugs And Devices Market size is expected to reach USD 4.80 billion in 2024 and grow at a CAGR of greater than 3.20% to reach USD 6.40 billion by 2029.
What is the current Japan Diabetes Drugs And Devices Market size?
In 2024, the Japan Diabetes Drugs And Devices Market size is expected to reach USD 4.80 billion.
Who are the key players in Japan Diabetes Drugs And Devices Market?
Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the Japan Diabetes Drugs And Devices Market.
What years does this Japan Diabetes Drugs And Devices Market cover, and what was the market size in 2023?
In 2023, the Japan Diabetes Drugs And Devices Market size was estimated at USD 4.65 billion. The report covers the Japan Diabetes Drugs And Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Japan Diabetes Drugs And Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Japan Diabetes Drugs And Devices Industry Report
Statistics for the 2024 Japan Diabetes Drugs and Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Japan Diabetes Drugs and Devices analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
